Only a few treatments are approved for coronavirus disease‐2019 (COVID‐19) infections,
with continuous debate about their clinical impact. Repurposing antiviral treatments might …

A simple, selective and stability-indicating high-pressure liquid chromatographic method was
developed for the analysis of ribavirin. Chromatographic separation was achieved by using …

BACKGROUND: Data from molecular docking, in-vitro experiments and 2 published small
clinical studies suggested a potential therapeutic benefit for the anti-hepatitis C drugs, …

Background In response to COVID-19 global crisis and arising from social responsibility,
efforts have been exerted to promptly research, develop and manufacture ICU ventilators …

BACKGROUND Preliminary data suggests a potential therapeutic benefit for the hepatitis C
drugs, sofosbuvir (SOF) and daclatasvir (DCV) for the treatment of COVID-19. We aim to …

COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to
the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved …

The maize single hybrid Giza 168 was evaluated for grain yield in a six-factor central composite
design in 2015 and 2016 summer seasons. The six factors included; surface irrigation …

Two field experiments were conducted at Agricultural Research Station, Faculty of Agriculture,
Alexandria University, Egypt, through summer seasons of 2015 and 2016 to investigate …

Background Human pegivirus (HPgV) is structurally similar to hepatitis C virus (HCV) and was
discovered 20 years ago. Its distribution, natural history and exact rule of this viral group in …

Background: Changes in DNA methylation patterns are believed to be early events in
hepatocarcinogenesis. A better understanding of methylation states and how they correlate with …